{"count": 14, "results": [{"_id": "34198358", "pmid": 34198358, "pmcid": "PMC9292486", "title": "Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis", "journal": "Br J Clin Pharmacol", "authors": ["Yen FS", "Huang YH", "Hou MC", "Hwu CM", "Lo YR", "Shin SJ", "Hsu CC"], "date": "2022-01-01T00:00:00Z", "doi": "10.1111/bcp.14970", "meta_date_publication": "2022 Jan", "meta_volume": "88", "meta_issue": "1", "meta_pages": "311-322", "score": 50262.04, "text_hl": "Hazards of @DISEASE_Death @DISEASE_MESH:D003643 @@@death@@@ and @<m>DISEASE_Idiopathic_Noncirrhotic_Portal_Hypertension</m> @DISEASE_MESH:D000094724 @@@cirrhotic@@@ decompensation due to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use seem to have dose relationship.  ", "citations": {"NLM": "Yen FS, Huang YH, Hou MC, Hwu CM, Lo YR, Shin SJ, Hsu CC. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis Br J Clin Pharmacol. 2022 Jan;88(1):311-322. PMID: 34198358", "BibTeX": "@article{34198358, title={Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis}, author={Yen FS and Huang YH and Hou MC and Hwu CM and Lo YR and Shin SJ and Hsu CC}, journal={Br J Clin Pharmacol}, volume={88}, number={1}, pages={311-322}}"}}, {"_id": "37664227", "pmid": 37664227, "pmcid": "PMC10433257", "title": "Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus", "journal": "Ann Gastroenterol", "authors": ["Huynh DJ", "Renelus BD", "Jamorabo DS"], "date": "2023-09-01T00:00:00Z", "doi": "10.20524/aog.2023.0814", "meta_date_publication": "2023 Sep-Oct", "meta_volume": "36", "meta_issue": "5", "meta_pages": "555-563", "score": 50256.684, "text_hl": "Dual @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and glucagon-like peptide-1 receptor agonist therapy reduces mortality and @DISEASE_Liver_Diseases @DISEASE_MESH:D008107 @@@hepatic complications@@@ in @<m>DISEASE_Idiopathic_Noncirrhotic_Portal_Hypertension</m> @DISEASE_MESH:D000094724 @@@cirrhotic@@@ @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes mellitus@@@", "citations": {"NLM": "Huynh DJ, Renelus BD, Jamorabo DS. Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus Ann Gastroenterol. 2023 Sep-Oct;36(5):555-563. PMID: 37664227", "BibTeX": "@article{37664227, title={Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus}, author={Huynh DJ and Renelus BD and Jamorabo DS}, journal={Ann Gastroenterol}, volume={36}, number={5}, pages={555-563}}"}}, {"_id": "36247416", "pmid": 36247416, "pmcid": "PMC9556255", "title": "Metformin-Associated Lactic Acidosis in a Diabetic Patient with Normal Kidney Function and Occult Cirrhosis", "journal": "Case Rep Crit Care", "authors": ["Chidiac J", "Kassab R", "Iskandar M", "Koubar S", "Aoun M"], "date": "2022-10-05T00:00:00Z", "doi": "10.1155/2022/5506744", "meta_date_publication": "2022", "meta_volume": "2022", "meta_issue": "", "meta_pages": "5506744", "score": 50244.06, "text_hl": " We discuss here the probable causes of severe @DISEASE_Acidosis_Lactic @DISEASE_MESH:D000140 @@@lactic acidosis@@@ and the role of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in exacerbating this acid-base @DISEASE_Voice_Disorders @DISEASE_MESH:D014832 @@@disturbance@@@ in @<m>DISEASE_Idiopathic_Noncirrhotic_Portal_Hypertension</m> @DISEASE_MESH:D000094724 @@@cirrhotic@@@ @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Chidiac J, Kassab R, Iskandar M, Koubar S, Aoun M. Metformin-Associated Lactic Acidosis in a Diabetic Patient with Normal Kidney Function and Occult Cirrhosis Case Rep Crit Care. 2022;2022():5506744. PMID: 36247416", "BibTeX": "@article{36247416, title={Metformin-Associated Lactic Acidosis in a Diabetic Patient with Normal Kidney Function and Occult Cirrhosis}, author={Chidiac J and Kassab R and Iskandar M and Koubar S and Aoun M}, journal={Case Rep Crit Care}, volume={2022}, pages={5506744}}"}}, {"_id": "36815548", "pmid": 36815548, "title": "Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study.", "journal": "Aliment Pharmacol Ther", "authors": ["Zhang X", "Yip TC", "Tse YK", "Hui VW", "Li G", "Lin H", "Liang LY", "Lai JC", "Lai MS", "Cheung JTK", "Chan HL", "Chan SL", "Kong AP", "Wong GL", "Wong VW"], "date": "2023-05-01T00:00:00Z", "doi": "10.1111/apt.17428", "meta_date_publication": "2023 May", "meta_volume": "57", "meta_issue": "10", "meta_pages": "1103-1116", "score": 50238.5, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and statins were underused in @<m>DISEASE_Idiopathic_Noncirrhotic_Portal_Hypertension</m> @DISEASE_MESH:D000094724 @@@cirrhotic@@@ @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Zhang X, Yip TC, Tse YK, Hui VW, Li G, Lin H, Liang LY, Lai JC, Lai MS, Cheung JTK, Chan HL, Chan SL, Kong AP, Wong GL, Wong VW. Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study. Aliment Pharmacol Ther. 2023 May;57(10):1103-1116. PMID: 36815548", "BibTeX": "@article{36815548, title={Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study.}, author={Zhang X and Yip TC and Tse YK and Hui VW and Li G and Lin H and Liang LY and Lai JC and Lai MS and Cheung JTK and Chan HL and Chan SL and Kong AP and Wong GL and Wong VW}, journal={Aliment Pharmacol Ther}, volume={57}, number={10}, pages={1103-1116}}"}}, {"_id": "25090757", "pmid": 25090757, "title": "[Do not stop metformin when the patient is cirrhotic].", "journal": "Rev Prat", "authors": ["Pariente A"], "date": "2014-06-01T00:00:00Z", "meta_date_publication": "2014 Jun", "meta_volume": "64", "meta_issue": "6", "meta_pages": "770", "score": 50083.49, "text_hl": "[Do not stop @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ when the @SPECIES_9606 @@@patient@@@ is @<m>DISEASE_Idiopathic_Noncirrhotic_Portal_Hypertension</m> @DISEASE_MESH:D000094724 @@@cirrhotic@@@].", "citations": {"NLM": "Pariente A. [Do not stop metformin when the patient is cirrhotic]. Rev Prat. 2014 Jun;64(6):770. PMID: 25090757", "BibTeX": "@article{25090757, title={[Do not stop metformin when the patient is cirrhotic].}, author={Pariente A}, journal={Rev Prat}, volume={64}, number={6}, pages={770}}"}}, {"_id": "26138461", "pmid": 26138461, "title": "Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.", "journal": "Am J Physiol Gastrointest Liver Physiol", "authors": ["Tripathi DM", "Erice E", "Lafoz E", "García-Calderó H", "Sarin SK", "Bosch J", "Gracia-Sancho J", "García-Pagán JC"], "date": "2015-09-01T00:00:00Z", "doi": "10.1152/ajpgi.00010.2015", "meta_date_publication": "2015 Sep 1", "meta_volume": "309", "meta_issue": "5", "meta_pages": "G301-9", "score": 50068.406, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ reduces @DISEASE_Chemical_and_Drug_Induced_Liver_Injury @DISEASE_MESH:D056486 @@@hepatic resistance@@@ and portal pressure in @<m>DISEASE_Idiopathic_Noncirrhotic_Portal_Hypertension</m> @DISEASE_MESH:D000094724 @@@cirrhotic@@@ @SPECIES_10116 @@@rats@@@.", "citations": {"NLM": "Tripathi DM, Erice E, Lafoz E, García-Calderó H, Sarin SK, Bosch J, Gracia-Sancho J, García-Pagán JC. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2015 Sep 1;309(5):G301-9. PMID: 26138461", "BibTeX": "@article{26138461, title={Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.}, author={Tripathi DM and Erice E and Lafoz E and García-Calderó H and Sarin SK and Bosch J and Gracia-Sancho J and García-Pagán JC}, journal={Am J Physiol Gastrointest Liver Physiol}, volume={309}, number={5}, pages={G301-9}}"}}, {"_id": "28676445", "pmid": 28676445, "title": "Metformin reduces intrahepatic fibrosis and intrapulmonary shunts in biliary cirrhotic rats.", "journal": "J Chin Med Assoc", "authors": ["Ko MT", "Huang HC", "Lee WS", "Chuang CL", "Hsin IF", "Hsu SJ", "Lee FY", "Chang CC", "Lee SD"], "date": "2017-08-01T00:00:00Z", "doi": "10.1016/j.jcma.2017.05.005", "meta_date_publication": "2017 Aug", "meta_volume": "80", "meta_issue": "8", "meta_pages": "467-475", "score": 50066.453, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ reduces intrahepatic @DISEASE_Fibrosis @DISEASE_MESH:D005355 @@@fibrosis@@@ and intrapulmonary shunts in biliary @<m>DISEASE_Idiopathic_Noncirrhotic_Portal_Hypertension</m> @DISEASE_MESH:D000094724 @@@cirrhotic@@@ @SPECIES_10116 @@@rats@@@.", "citations": {"NLM": "Ko MT, Huang HC, Lee WS, Chuang CL, Hsin IF, Hsu SJ, Lee FY, Chang CC, Lee SD. Metformin reduces intrahepatic fibrosis and intrapulmonary shunts in biliary cirrhotic rats. J Chin Med Assoc. 2017 Aug;80(8):467-475. PMID: 28676445", "BibTeX": "@article{28676445, title={Metformin reduces intrahepatic fibrosis and intrapulmonary shunts in biliary cirrhotic rats.}, author={Ko MT and Huang HC and Lee WS and Chuang CL and Hsin IF and Hsu SJ and Lee FY and Chang CC and Lee SD}, journal={J Chin Med Assoc}, volume={80}, number={8}, pages={467-475}}"}}, {"_id": "28705726", "pmid": 28705726, "title": "Dual organ beneficial effects of metformin in cirrhotic rats with hepatopulmonary syndrome.", "journal": "J Chin Med Assoc", "authors": ["Liu CW", "Yang YY"], "date": "2017-08-01T00:00:00Z", "doi": "10.1016/j.jcma.2017.05.007", "meta_date_publication": "2017 Aug", "meta_volume": "80", "meta_issue": "8", "meta_pages": "463-464", "score": 50066.406, "text_hl": "Dual organ beneficial effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @<m>DISEASE_Idiopathic_Noncirrhotic_Portal_Hypertension</m> @DISEASE_MESH:D000094724 @@@cirrhotic@@@ @SPECIES_10116 @@@rats@@@ with @DISEASE_Hepatopulmonary_Syndrome @DISEASE_MESH:D020065 @@@hepatopulmonary syndrome@@@.", "citations": {"NLM": "Liu CW, Yang YY. Dual organ beneficial effects of metformin in cirrhotic rats with hepatopulmonary syndrome. J Chin Med Assoc. 2017 Aug;80(8):463-464. PMID: 28705726", "BibTeX": "@article{28705726, title={Dual organ beneficial effects of metformin in cirrhotic rats with hepatopulmonary syndrome.}, author={Liu CW and Yang YY}, journal={J Chin Med Assoc}, volume={80}, number={8}, pages={463-464}}"}}, {"_id": "29209957", "pmid": 29209957, "title": "Salvianolate Reduces Glucose Metabolism Disorders in Dimethylnitrosamine-Induced Cirrhotic Rats.", "journal": "Chin J Integr Med", "authors": ["Tang LR", "Tao YY", "Liu CH", "Wang HN"], "date": "2018-09-01T00:00:00Z", "doi": "10.1007/s11655-017-2773-5", "meta_date_publication": "2018 Sep", "meta_volume": "24", "meta_issue": "9", "meta_pages": "661-669", "score": 50060.418, "text_hl": "The @<m>DISEASE_Idiopathic_Noncirrhotic_Portal_Hypertension</m> @DISEASE_MESH:D000094724 @@@cirrhotic@@@ @SPECIES_10116 @@@rats@@@ were divided into model, Sal B and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ groups (n=15), respectively. ", "citations": {"NLM": "Tang LR, Tao YY, Liu CH, Wang HN. Salvianolate Reduces Glucose Metabolism Disorders in Dimethylnitrosamine-Induced Cirrhotic Rats. Chin J Integr Med. 2018 Sep;24(9):661-669. PMID: 29209957", "BibTeX": "@article{29209957, title={Salvianolate Reduces Glucose Metabolism Disorders in Dimethylnitrosamine-Induced Cirrhotic Rats.}, author={Tang LR and Tao YY and Liu CH and Wang HN}, journal={Chin J Integr Med}, volume={24}, number={9}, pages={661-669}}"}}, {"_id": "23166628", "pmid": 23166628, "pmcid": "PMC3499552", "title": "Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy", "journal": "PLoS One", "authors": ["Ampuero J", "Ranchal I", "Nuñez D", "Díaz-Herrero Mdel M", "Maraver M", "del Campo JA", "Rojas Á", "Camacho I", "Figueruela B", "Bautista JD", "Romero-Gómez M"], "date": "2012-01-01T00:00:00Z", "doi": "10.1371/journal.pone.0049279", "meta_date_publication": "2012", "meta_volume": "7", "meta_issue": "11", "meta_pages": "e49279", "score": 50053.465, "text_hl": "In spite of all these data support an active effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @<m>DISEASE_Idiopathic_Noncirrhotic_Portal_Hypertension</m> @DISEASE_MESH:D000094724 @@@cirrhotics@@@, a selection bias could not be excluded in a retrospective analysis. ", "citations": {"NLM": "Ampuero J, Ranchal I, Nuñez D, Díaz-Herrero Mdel M, Maraver M, del Campo JA, Rojas Á, Camacho I, Figueruela B, Bautista JD, Romero-Gómez M. Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy PLoS One. 2012;7(11):e49279. PMID: 23166628", "BibTeX": "@article{23166628, title={Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy}, author={Ampuero J and Ranchal I and Nuñez D and Díaz-Herrero Mdel M and Maraver M and del Campo JA and Rojas Á and Camacho I and Figueruela B and Bautista JD and Romero-Gómez M}, journal={PLoS One}, volume={7}, number={11}, pages={e49279}}"}}]}